Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics
GET POWR RATINGS... FREE!
SRRK POWR Grades
- Momentum is the dimension where SRRK ranks best; there it ranks ahead of 49.41% of US stocks.
- SRRK's strongest trending metric is Growth; it's been moving down over the last 200 days.
- SRRK's current lowest rank is in the Growth metric (where it is better than 9.41% of US stocks).
SRRK Stock Summary
- With a price/sales ratio of 63.62, Scholar Rock Holding Corp has a higher such ratio than 95.62% of stocks in our set.
- With a year-over-year growth in debt of 977.48%, Scholar Rock Holding Corp's debt growth rate surpasses 98.25% of about US stocks.
- In terms of volatility of its share price, SRRK is more volatile than 91.31% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Scholar Rock Holding Corp, a group of peers worth examining would be ARCT, ENTA, MTEM, DTIL, and ZYME.
- SRRK's SEC filings can be seen here. And to visit Scholar Rock Holding Corp's official web site, go to scholarrock.com.
SRRK Price Target
For more insight on analysts targets of SRRK, see our SRRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $71.00 | Average Broker Recommendation | 1.3 (Strong Buy) |
SRRK Stock Price Chart Interactive Chart >
SRRK Price/Volume Stats
| Current price | $28.60 | 52-week high | $70.00 |
| Prev. close | $29.82 | 52-week low | $10.28 |
| Day low | $28.35 | Volume | 155,800 |
| Day high | $30.00 | Avg. volume | 288,004 |
| 50-day MA | $42.96 | Dividend yield | N/A |
| 200-day MA | $36.69 | Market Cap | 983.64M |
Scholar Rock Holding Corporation (SRRK) Company Bio
Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.
Latest SRRK News From Around the Web
Below are the latest news stories about Scholar Rock Holding Corp that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in TherapyScholar Rock announced that findings from its Phase 1 trial of apitemograb were published in the peer-reviewed journal Advances in Therapy. |
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q1 Earnings Expected to DeclineScholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRKNEW YORK, April 24, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation (“Scholar Rock” or the “Company”) (NASDAQ: SRRK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Scholar Rock and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 6, 2021, Scholar Rock issued a press release announcing what the Company described as “Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)”. While the p... |
Scholar Rock Stock Shows Market Leadership With Healthy Jump To 83 RS RatingScholar RockHldgCrp shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 83. |
3 Beaten-Down Biotech Stocks: Can They Recover?The past month has been awfully hard on biotech stocks across the board. Follow-up data for apitegromab didn't set off fireworks as hoped, but an approach that includes a drug that prevents progressive nerve damage for SMA patients seems likely to succeed. |
SRRK Price Returns
| 1-mo | 0.99% |
| 3-mo | -47.47% |
| 6-mo | -33.89% |
| 1-year | 55.35% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -41.07% |
| 2020 | 268.21% |
| 2019 | -42.62% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching SRRK
Here are a few links from around the web to help you further your research on Scholar Rock Holding Corp's stock as an investment opportunity:Scholar Rock Holding Corp (SRRK) Stock Price | Nasdaq
Scholar Rock Holding Corp (SRRK) Stock Quote, History and News - Yahoo Finance
Scholar Rock Holding Corp (SRRK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...